Cytovale(R) today announced new multicenter, real-world data demonstrating that clinical and operational improvements in sepsis care first observed at a high-volume emergency department (ED) in Baton ...
Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-Melanoma webcast to review results ...
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results